Research shows targeted therapies can improve health outcomes and ineffective treatments can exacerbate physical, emotional and financial burdens. CLL Society joins with fellow advocates in support of state legislation to align insurance coverage of evidence based biomarker testing to insure less trial and error in prescribing medications, improve patients’ lives and reduce the burden of health care costs.
Similar legislation has been passed in several states, and CLL Society and others continue to advocate for similar laws in the remaining states. Read the California letter here.
